18 March 2013
Liesbeth, Sara and Steffen attended the first Annual National Haematological PhD course: “From Scientific Idea to New Targeted Therapy – how to commercialize science”, organized by the University of Southern Denmark. This 2-day course took place in March at the Hindsgavl Slot in Middelfart. Commercialization of scientific projects was under discussion, and the development of a new monoclonal antibody with anti-neoplastic properties was presented, spanning the process from the identification of a cellular target through clinical evaluation to the final European Medicines Agency registration. All students were asked to discuss the commercial potential of their project.
Sara presented the poster “Functional analysis of microRNA-dependent chemosensitivity in B-cell cancers by lentiviral transduction in human cancer B-cell lines”,Steffen presented the poster “Generation of a cell line derived gene signature predictor of response to Doxorubicin in Diffuse Large B-Cell Lymphoma” and Liesbeth’s poster title was “Combination of the IGF-1 receptor inhibitor picropodophyllin (PPP) and the BH3 mimetic ABT-737 has synergistic anti-myeloma activity”, for which she received the best poster presentation award.